Steady-state pharmacokinetics and dose proportionality of troglitazone and its metabolites

Journal of Clinical Pharmacology

Volumn 39, Issue 9, 1999, Pages 920-926

  Loi, C M ^a   Alvey, C W ^a   Vassos, A B ^a   Randinitis, E J ^a   Sedman, A J ^a   Koup, J R ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; TROGLITAZONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; STEADY STATE;

EID: 0033309229     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922008533     Document Type: Article

References (12)

1. Troglitazone (CS-045), a new antidiabetic drug
2. Sulfonylurea drugs: Mechanism of antidiabetic action and therapeutic usefulness
3. Metformin
4. Troglitazone
5. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM
6. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects
7. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone
8. Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach
9. Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study
10. Meta-analysis of steady-state pharmacokinetics of troglitazone and its metabolites
11. Improvement in the gastrointestinal absorption of troglitazone when taken with, or shortly after, food